Role of Medical and Surgical Treatment in Management of the Patients With Prolactinoma: A Single-Center Experience

Abstract

Background Current guidelines recommend dopamine agonists (DA) as the primary therapeutic approach for prolactinomas; however, emerging evidence suggests that surgical intervention can also yield favorable outcomes.

Objective To comprehensively evaluate prolactinoma patients undergoing surgical and medical treatments at our pituitary center.

Methods Retrospective review of mMedical records from prolactinoma patients treated between 2015 and 2022 was performedwere retrospectively reviewed. The study focused on treatment outcomes and remission rates while investigating factors influencing the success of both treatment modalities in achieving remission.

Results A total of 301 prolactinoma patients were included, of whom 199 were women. Among them, 235 were managed medically, while 66 underwent surgical intervention. The overall remission rates of patients treated with medical and surgery were similar at the final examination (Respectively respectively 82.9% and 81.8%, p=0.114). Factors associated with remission in both treatment modalities included female sex, low initial prolactin levels, small adenoma size, and absence of cavernous invasion. Compared to DA treatment, Ssurgical treatment demonstrated a higher rate of drug-free remission compared to DA treatment for microadenomas, and macroadenomas without cavernous invasion. In cases with cavernous invasion, standalone surgical treatment yielded a low rate of drug-free remission (7.7%); however, when combined with DA therapy post-surgery, remission rates increased to 66.7%.

Conclusion Medical treatment with DAs remains the preferred option for macroadenomas with cavernous sinus invasion, and giant adenomas, with surgery reserved for selected cases to address complications. Conversely, surgery emerges as the most effective modality for achieving remission in patients with microadenomas, and macroadenomas confined to the sella. The recommendation of DAs as first-line therapy for all patients has been withdrawn in the current guidelines, and individual treatment approaches based on tumor characteristics are emphasized. Our results support this approach.

Keywords

endoscopic transsphenoidal surgery - dopamine agonists - prolactinoma - remission - treatment

Publikationsverlauf

Eingereicht: 27. März 2024

Angenommen nach Revision: 11. Juli 2024

Accepted Manuscript online:
11. Juli 2024

Artikel online veröffentlicht:
30. August 2024

• References

• 1 Friesen HG. The discovery of human prolactin: A very personal account. Clin Invest Med 1995; 18: 66-72
• 2 Liu JK, Das K, Weiss MH. et al. The history and evolution of transsphenoidal surgery. J Neurosurg 2001; 95: 1083-1096 DOI: 10.3171/jns.2001.95.6.1083.
• 3 Schlechte J, Sherman B, Halmi N. et al. Prolactin-secreting pituitary tumors in amenorrheic women: A comprehensive study. Endocr Rev 1980; 1: 295-308 DOI: 10.1210/edrv-1-3-295.
• 4 Beach FA. Historical origins of modern research on hormones and behavior. Horm Behav 1981; 15: 325-376 DOI: 10.1016/0018-506x(81)90001-5.
• 5 Freeman ME, Kanyicska B, Lerant A. et al. Prolactin: Structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1631 DOI: 10.1152/physrev.2000.80.4.1523.
• 6 Bevan JS, Webster J, Burke CW. et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 220-240 DOI: 10.1210/edrv-13-2-220.
• 7 Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288 DOI: 10.1210/jc.2010-1692.
• 8 Khan DZ, Hanrahan JG, Baldeweg SE. et al. Current and future advances in surgical therapy for pituitary adenoma. Endocr Rev 2023; 44: 947-959 DOI: 10.1210/endrev/bnad014.
• 9 Andereggen L, Frey J, Andres RH. et al. First-line surgery in prolactinomas: Lessons from a long-term follow-up study in a tertiary referral center. J Endocrinol Invest 2021; 44: 2621-2633 DOI: 10.1007/s40618-021-01569-6.
• 10 Honegger J, Nasi-Kordhishti I, Aboutaha N. et al. Surgery for prolactinomas: A better choice?. Pituitary 2020; 23: 45-51 DOI: 10.1007/s11102-019-01016-z.
• 11 Brenton RS, Phelps CD. The normal visual field on the Humphrey field analyzer. Ophthalmologica 1986; 193: 56-74 DOI: 10.1159/000309679.
• 12 Mohr G, Hardy J, Comtois R. et al. Surgical management of giant pituitary adenomas. Can J Neurol Sci 1990; 17: 62-66 DOI: 10.1017/s0317167100030055.
• 13 Knosp E, Steiner E, Kitz K. et al. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610-618 DOI: 10.1227/00006123-199310000-00008.
• 14 Duskin-Bitan H, Shimon I. Prolactinomas in males: Any differences?. Pituitary 2020; 23: 52-57 DOI: 10.1007/s11102-019-01009-y.
• 15 Dzialach L, Sobolewska J, Zak Z. et al. Prolactin-secreting pituitary adenomas: Male-specific differences in pathogenesis, clinical presentation and treatment. Front Endocrinol (Lausanne) 2024; 15: 1338345 DOI: 10.3389/fendo.2024.1338345.
• 16 Ozaydin D, Demir AN, Tanriover N. Evaluation of the gender effect in operated prolactinomas. Eur Res J 2023; 9: 1135-1141 DOI: 10.18621/eurj.1340508.
• 17 Delgrange E, Trouillas J, Maiter D. et al. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 1997; 82: 2102-2107 DOI: 10.1210/jcem.82.7.4088.
• 18 Nishioka H, Haraoka J, Akada K. Growth potential of prolactinomas in men: Is it really different from women?. Surg Neurol 2003; 59: 386-391 DOI: 10.1016/s0090-3019(03)00012-0.
• 19 Ambulkar SS, Darves-Bornoz AL, Fantus RJ. et al. Prevalence of hyperprolactinemia and clinically apparent prolactinomas in men undergoing fertility evaluation. Urology 2022; 159: 114-119 DOI: 10.1016/j.urology.2021.03.007.
• 20 Colao A, Sarno AD, Cappabianca P. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003; 148: 325-331 DOI: 10.1530/eje.0.1480325.
• 21 Kadioglu P, Oral G, Sayitoglu M. et al. Aromatase cytochrome P450 enzyme expression in human pituitary. Pituitary 2008; 11: 29-35 DOI: 10.1007/s11102-007-0065-3.
• 22 Akinci H, Kapucu A, Dar KA. et al. Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior. Pituitary 2013; 16: 386-392 DOI: 10.1007/s11102-012-0436-2.
• 23 Calle-Rodrigue RD, Giannini C, Scheithauer BW. et al. Prolactinomas in male and female patients: A comparative clinicopathologic study. Mayo Clin Proc 1998; 73: 1046-1052 DOI: 10.4065/73.11.1046.
• 24 Schaller B. Gender-related differences in prolactinomas. A clinicopathological study [published correction in Neuro Endocrinol Lett 2005; 26: 628]. Neuro Endocrinol Lett 2005; 26: 152-159
• 25 Fainstein Day P, Glerean M, Lovazzano S. et al. Gender differences in macroprolactinomas: Study of clinical features, outcome of patients and ki-67 expression in tumor tissue. Front Horm Res 2010; 38: 50-58 DOI: 10.1159/000318494.
• 26 Delgrange E, Sassolas G, Perrin G. et al. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 2005; 147: 751-758 DOI: 10.1007/s00701-005-0498-2.
• 27 Auriemma RS, Pirchio R, Pivonello C. et al. Approach to the patient with prolactinoma. J Clin Endocrinol Metab 2023; 108: 2400-2423 DOI: 10.1210/clinem/dgad174.
• 28 Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 2019; 33: 101290 DOI: 10.1016/j.beem.2019.101290.
• 29 Tampourlou M, Trifanescu R, Paluzzi A. et al. Therapy of endocrine disease: Surgery in microprolactinomas: Eeffectiveness and risks based on contemporary literature. Eur J Endocrinol 2016; 175: R89-R96 DOI: 10.1530/EJE-16-0087.
• 30 Losa M, Mortini P, Barzaghi R. et al. Surgical treatment of prolactin-secreting pituitary adenomas: Early results and long-term outcome. J Clin Endocrinol Metab 2002; 87: 3180-3186 DOI: 10.1210/jcem.87.7.8645.
• 31 Wolfsberger S, Czech T, Vierhapper H. et al. Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir (Wien) 2003; 145: 935-941 DOI: 10.1007/s00701-003-0134-y.
• 32 Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F. et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab 2020; 105: e32-e41 DOI: 10.1210/clinem/dgz144.
• 33 Casanueva FF, Barkan AL, Buchfelder M. et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement [published correction in Pituitary 2018 20]. Pituitary 2017; 20: 489-498 DOI: 10.1007/s11102-017-0838-2.
• 34 Cozzi R, Ambrosio MR, Attanasio R. et al. Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: Prolactin-secreting tumors. Eur J Endocrinol 2022; 186: P1-P33 DOI: 10.1530/EJE-21-0977.
• 35 Basile M, Valentini I, Attanasio R. et al. A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas. Glob Reg Health Technol Assess 2024; 11: 1-16 DOI: 10.33393/grhta.2024.2601.
• 36 Petersenn S, Fleseriu M, Casanueva FF. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: A Pituitary Society International Consensus Statement. [published correction in Nat Rev Endocrinol 2023]. Nat Rev Endocrinol 2023; 19: 722-740 DOI: 10.1038/s41574-023-00886-5.
• 37 Zandbergen IM, Huntoon KM, White TG. et al. Efficacy and safety of endoscopic transsphenoidal resection for prolactinoma: A retrospective multicenter case-series. Arch Med Res 2023; 54: 102919 DOI: 10.1016/j.arcmed.2023.102919.
• 38 Demir D, Demir AN, Sulu C. et al. The combination of dopamine agonist treatment and surgery may be the best option in challenging prolactinoma cases: A single-centre experience. World Neurosurg 2023; 175: e1166-e1174 DOI: 10.1016/j.wneu.2023.04.089.
• 39 Kreutzer J, Buslei R, Wallaschofski H. et al. Operative treatment of prolactinomas: Indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 2008; 158: 11-18 DOI: 10.1530/EJE-07-0248.
• 40 Mohr G, Hardy J, Comtois R. et al. Surgical management of giant pituitary adenomas. Can J Neurol Sci 1990; 17: 62-66 DOI: 10.1017/s0317167100030055.
• 41 Koutourousiou M, Gardner PA, Fernandez-Miranda JC. et al. Endoscopic endonasal surgery for giant pituitary adenomas: Advantages and limitations. J Neurosurg 2013; 118: 621-631 DOI: 10.3171/2012.11.JNS121190.
• 42 Ke D, Xu L, Wu D. et al. Surgical management of giant pituitary adenomas: Institutional experience and clinical outcomes of 94 patients. Front Oncol 2023; 13: 1255768 DOI: 10.3389/fonc.2023.1255768.
• 43 Shrivastava RK, Arginteanu MS, King WA. et al. Giant prolactinomas: Clinical management and long-term follow up. J Neurosurg 2002; 97: 299-306 DOI: 10.3171/jns.2002.97.2.0299.
• 44 Chen Z, Shou X, Ji L. et al. Presurgical medical treatment in prolactinomas: Surgical implications and pathological characteristics from 290 cases. J Clin Endocrinol Metab 2024; 109: 1433-1442 DOI: 10.1210/clinem/dgad758.
• 45 De Sousa SMC, Jukes AK, Candy NG. et al. Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern. Nat Rev Endocrinol 2024; 20: 314 DOI: 10.1038/s41574-024-00976-y.
• 46 Jethwa PR, Patel TD, Hajart AF. et al. Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg 2016; 87: 65-76 DOI: 10.1016/j.wneu.2015.10.090.